Martek

Martek is star performer in DSM's nutrition division in Q3

Martek is star performer in DSM's nutrition division in Q3

By Elaine Watson

Martek “clearly exceeded expectations” in the third quarter for new owner DSM within a nutrition division that continued to deliver “robust” results despite the negative impact of currency translation.

Martek: End of an era

Martek name to disappear as DSM creates new Nutritional Lipids business

By Elaine Watson

Seven months after sealing a billion dollar deal to acquire Martek, DSM has created Nutritional Lipids, a new division that will combine Martek’s algal omega-3 and omega-6 products and DSM Nutritional Products’ polyunsaturated fatty acid (PUFA) portfolio.

AlgaeBio unveils production stats as algal omega-3 market heats up

AlgaeBio unveils production stats as algal omega-3 market heats up

By Elaine Watson

Algae Biosciences Corporation – a high-profile new entrant to the omega-3 fatty acid market – has unveiled detailed figures on anticipated production volumes after finalizing a deal to build the first phase of its new production facility near Holbrook...

DSM reports successful tender offer for Martek

DSM reports successful tender offer for Martek

By Mike Stones

Royal DSM’s acquisition of Martek Biosciences Corporation has moved a step closer to finalisation with the news that its tender offer to buy all of the company’s outstanding shares of common stock at a price of $31.50 (about €24) per share has proved...

Martek becomes DSM's biggest acquisition since its 2002 purchase of Roche Vitamins

DSM buys Martek’s “algae platform” for $1bn+

By Shane Starling

Royal DSM will drive Martek’s predominantly US-based, omega-3 DHA infant nutrition business to new shores, and fast-track its food and beverage ambitions, after having its billion-dollar bid accepted by the Maryland company’s Board.

DSM to double ARA output

DSM to double ARA output

DSM Food Specialties is to double the volume of arachidonic acid
(ARA) produced for its US partner Martek Biosciences to meet
rapidly growing demand, the Dutch firm said this week, writes
Dominique Patton.

Martek development pays off

Martek development pays off

Martek Biosciences has reported a 132 per cent increase in revenues
to $26.4 million for the second quarter of the year, thanks to
greater sales of nutritional products to the company's infant
formula licensees, Wyeth, Mead Johnson...

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All